Adherence with brand versus generic bisphosphonates among osteoporosis patients: a new-user cohort study in the French National Healthcare Insurance database

• Published in: Scientific reports Vol. 10; no. 1; p. 7446
• Main Authors: Viprey, Marie, Xue, Yufeng, Rousseau, Aurélie, Payet, Cécile, Chapurlat, Roland, Caillet, Pascal, Dima, Alexandra, Schott, Anne-Marie
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 04.05.2020; Nature Publishing Group
• Subjects: 692/4023; 692/700/565/809; Administration, Oral; Aged; Aged, 80 and over; Bisphosphonates; Bone Density Conservation Agents - therapeutic use; Cohort analysis; Databases, Factual; Diphosphonates - therapeutic use; Drugs, Generic - therapeutic use; Female; France; Health care; Human health and pathology; Humanities and Social Sciences; Humans; Insurance, Health; Life Sciences; Male; Medication; Medication Adherence; Middle Aged; multidisciplinary; Osteoporosis; Osteoporosis - drug therapy; Pharmaceutical sciences; Propensity Score; Proportional Hazards Models; Retrospective Studies; Rhumatology and musculoskeletal system; Risk; Santé publique et épidémiologie; Science; Science (multidisciplinary); France
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-020-64214-x

Several studies documented declines in treatment adherence with generic forms of oral bisphosphonates in osteoporosis compared to branded forms, while others did not support this relation. Our aim was to compare medication adherence with brand versus generic forms of oral bisphosphonates. A new-user cohort study was conducted using routinely collected administrative and healthcare data linked at the individual level extracted from a nationwide representative sample of the French National Healthcare Insurance database. We included all patients aged 50 and older, new users of oral bisphosphonates for primary osteoporosis between 01/01/2009 and 31/12/2015. Two components of adherence were measured: implementation (continuous multiple-interval measure of medication availability version 7; CMA7) and persistence (time to discontinuation). The sample was composed of 1,834 in the “brand bisphosphonate” group and 1,495 patients in the “generic bisphosphonate” group. Initiating oral bisphosphonate treatment with brand was associated with a higher risk of discontinuation within 12 months (Hazard Ratio = 1.08; 95%CI = [1.02;1.14]). The risk of good implementation (CMA7 ≥ 0.90) was significantly lower in “brand bisphosphonate” group (Risk Ratio = 0.90; 95%CI = [0.85; 0.95]). We did not find any evidence to support the hypothesis of a lower adherence to generic bisphosphonates. In fact, prescribing of generic bisphosphonates led to a higher persistence rate and to better implementation at 1 year.